Table 1 Subgroup analysis in three comparison (RCTs or non-RCTs).

From: Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia

Comparison

Survival outcome

Study design

Odds ratio (95% CI)

Number of study

AMD vs. Control

Short-term

RCT

1.61 (1.03–2.49)*

4

non-RCT

1.04 (0.61–1.77)

9

Long-term

RCT

1.13 (0.95–1.33)

3

non-RCT

0.93 (0.46–1.87)

9

NIF vs. Control

Short-term

RCT

15.03 (5.02–44.99)*

2

non-RCT

2.80 (2.04–3.86)*

10

Long-term

RCT

11.32 (0.49–259.07)

1

non-RCT

1.84 (1.33–2.54)*

9

AMD vs. NIF

Short-term

RCT

2.29 (0.52–10.01)

1

non-RCT

0.80 (0.61–1.05)

10

Long-term

RCT

3.14 (0.68–14.50)

1

non-RCT

1.04 (0.53–2.05)

4

  1. Abbreviation: AMD, amiodarone; NIF, nifekalant; RCT, randomized controlled trial; CI, confidence interval. *p < 0.05.